Applied Genetic Technologies Corporation
12085 Research Drive
Suite 110
Alachua
Florida
32615
United States
Tel: 386-462-0880
Fax: 386-462-0875
Website: http://www.agtcfl.com/
152 articles about Applied Genetic Technologies Corporation
-
AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
9/27/2021
Applied Genetic Technologies Corporation today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference at 1:20 p.m.
-
AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021
9/23/2021
-Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022-
-
AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021
9/16/2021
Applied Genetic Technologies Corporation today announced that it will report financial results for the quarter and year ended June 30, 2021 after the market closes on Thursday, September 23, 2021.
-
AGTC to Participate in Clinical Trials in Rare Diseases Conference Panel and Case StudyAGTC patient advocacy executive director and director of patient enrollment to speak at Clinical Trials in Rare Diseases Conference
9/9/2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), today announced that Jill Dolgin, PharmD, Executive Director of Global Patient Advocacy, and Halley Losekamp, Director of Patient Enrollment, will participate as speakers at the Clinical Trials in Rare Diseases Conference,
-
AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/7/2021
Applied Genetic Technologies Corporation today announced that management will be participating in a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th, 2021.
-
AGTC to Present at the 2021 Wells Fargo Virtual Healthcare Conference
9/2/2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in a fireside chat at the 2021 Wells Fargo Virtual Healthcare Conference.
-
AGTC Appoints Ophthalmology and Retinal Disease Specialist and Industry R&D Veteran Yehia Hashad, MD to its Board of Directors
8/18/2021
Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare retinal diseases, announced the addition of Yehia Hashad, MD to its Board of Directors.
-
AGTC to Participate in Envision Virtual Conference East 2021 Panel Discussion
8/16/2021
Applied Genetic Technologies Corporation today announced that Jill Dolgin, PharmD, Executive Director of Global Patient Advocacy, will participate in a panel discussion at the Envision Virtual Conference East 2021, August 20-21.
-
AGTC to Participate at Upcoming Investor Conferences - Aug 02, 2021
8/2/2021
Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare retinal diseases, announced that management will be participating in the following virtual investor conferences.
-
AGTC to Host Virtual R&D Day on July 22, 2021
7/8/2021
Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare retinal diseases, announced that it will host a virtual R&D Day from 10:00 am to 1:00 pm ET on Thursday, July 22, 2021.
-
AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene
6/24/2021
Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare retinal diseases, reported 12-month data from its ongoing achromatopsia Phase 1/2 clinical trials, including data from all adult patients and low-dose pediatric patients.
-
AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials
6/23/2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it plans to release 12-month data for adult patients and low dose pediatric patients in its Phase 1/2 clinical Achromatopsia (ACHM) trials on Thursday, June 24, 2021.
-
AGTC to Present at American Optometric Association’s Optometry’s Meeting
6/22/2021
Applied Genetic Technologies Corporation announced that Jill Dolgin, PharmD, Executive Director of Global Patient Advocacy, will address optometric graduate students on the topic of inherited retinal diseases at the 124th Annual American Optometric Association Congress & 51st Annual American Optometric Student Association Conference: Optometry's Meeting®, being held June 24-26 in Denver.
-
AGTC Expands Leadership Team with Appointment of Key Regulatory Leader
5/26/2021
Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare retinal diseases, announced the appointment of Janet C. Rae, RAC, as Senior Vice President of Global Regulatory and Quality.
-
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2021
5/17/2021
Reported 50% response rate in visual sensitivity among patients in highest dose groups in ongoing Phase 1/2 clinical trial of its XLRP gene therapy candidate for patients who met inclusion criteria for Skyline and Vista trials
-
AGTC Announces Expansion of Manufacturing and Analytics Capabilities to Advance Commercialization of Gene Therapy Product Candidates
5/13/2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has initiated plans to lease a build-to-suit 21,000 square foot current Good Manufacturing Practices (cGMP) manufacturing and quality control facility adjacent to its Florida facility
-
AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 17, 2021
5/11/2021
Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare retinal diseases, announced that it will report financial results for the fiscal quarter ended March 31, 2021 after the market closes on Monday, May 17, 2021.
-
AGTC Reports Process Development Advances for Manufacturing its XLRP Gene Therapy Candidate in Two Abstracts at ASGCT
5/11/2021
Improved process and validated expression assay support clinical phase product release for the Vista Phase 2/3 XLRP clinical trial
-
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial
5/6/2021
Data from a subset of Group 4 patients available for analysis at 24 months also provide preliminary evidence of continued durable responses and continue to demonstrate a favorable safety profile
-
AGTC to Host Conference Call on May 6 at 8:00 AM ET to Discuss XLRP Full 12-Month Data from Highest Dose Groups and 24-Month Data from a Subset of Group 4 Patients of its Ongoing Phase 1/2 Clinical Trial
5/5/2021
Applied Genetic Technologies Corporation announced that it plans to release 12-month data for Groups 5 and 6 evaluating durability of effect and continued safety at higher doses and 24-month data evaluating durability from a subset of Group 4 patients for its Phase 1/2 clinical trial in patients with X-linked Retinitis Pigmentosa on Thursday, May 6, 2021.